COVID-19 vaccine effectiveness
(Randomized evidence)

Methods

Protocol

Analyses are updated every two weeks

meta-COVID

Perform your own analysis using COVID-NMA data, create and download your forest plots by clicking below:

go to metacovid

Vaccine types

Vaccine efficacy and safety for vaccine vs placebo / no vaccine (forest plots)

Vaccine efficacy and safety for vaccine vs vaccine (forest plots)

Vaccine efficacy and safety against variants of concern (forest plots)

Vaccine efficacy, immunogenicity and safety of heterologous vs homologous vaccination (tables)

Vaccine efficacy, immunogenicity and safety of booster vs no booster (tables)

Vaccine efficacy, immunogenicity and safety of booster VS booster (tables)

Trials reports under extraction

In addition to the below included trials, we have included and presently extracting 24 new vaccine randomized trials

Description of primary studies

In this table, we report the main characteristics of the COVID-19 vaccine candidates from RCTs identified, in addition to the overall risk of bias assessment.

As of January 2022, we will extract and present results of early phase trials only when the dose has been selected. Results from phase 1-2 studies are included in forest plots for the chosen vaccine dose and schedule only.

Search studies

Search by Vaccine name Author Registration number
Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT05158855
DreamTec Research Limited
Sung J, Vaccines, 2022
New

Full text
Commentary
Commentary
Heterologous booster

BNT162b2 or BBIBP/boost Recombinant Bacillus subtilis

BNT162b2 or BBIBP/boost Adjuvant

RCT
*
Healthy adult volunteers that were HIV-negative and SARS-CoV-2 infection-free in a single centre in China. N=16
Some concerns
Details

Full description

TCTR20210923012
Pfizer/BioNTech+Fosun Pharma
Puthanakit T, Vaccine: X, 2022 b
New

Full text
Commentary
RNA based vaccine

Boost BNT162b2 15 mcg after prime vaccination Coronavac/BNT162b2

Boost BNT162b2 10 mcg after prime vaccination Coronavac/BNT162b2

Boost BNT162b2 30mcg after prime vaccination Coronavac/BNT162b2

RCT
Phase 2
Healthy adolescents with no prior COVID-19 infection or vaccination at a single center in Thailand. N=52
Some concerns
Details

Full description

NCT05142553
Laboratorios Hipra, S.A. ; Pfizer/BioNTech + Fosun Pharma
Corominas J, medRxiv, 2022
New

Full text
Commentary
Commentary
Heterologous booster

BNT162b2/boostPHH-IV

BNT162b2/boostBNT

RCT
Phase 2b
Healthy adults with no history of COVID-19 in 10 centres in Spain. N=782
Some concerns
Details

Full description

TCTR20210923012
Sinovac; Pfizer/BioNTech+Fosun Pharma
Puthanakit T, Vaccine: X, 2022 a
New

Full text
Commentary
Heterologous vaccination scheme

CoronaVac followed by BNT162b2 30 at 6week interva

CoronaVac followed by BNT162b2 20 at 3week interva

CoronaVac followed by BNT162b2 20 at 6week interva

CoronaVac followed by BNT162b2 30 at 3week interva

RCT
Phase 2
Healthy adolescents with no prior COVID-19 infection or vaccination at a single center in Thailand. N=76
Some concerns
Details

Full description

IRCT20150303021315N23 ; NCT04944368
Vaxine/CinnaGen
Tabarsi P, CMI, 2022
New

Full text
Commentary
Protein subunit

SpikoGen 2 doses 25mcg D0/21

Placebo

RCT
Phase 2
Healthy adults or those with stable medical conditions, with or without prior COVID-19 infection, at a single center in Iran. N=400
Some concerns
Details

Full description

NCT04952727
CanSino Biological Inc./Beijing Institute of Biotechnology ; Sinovac Research and Development Co., Ltd
Jin P, medRxiv, 2022 a
New

Full text
Commentary
Commentary
Non replicating viral vector

CoronaVac/Boost Ad5-vectored 5×10^10 vp

CoronaVac/Boost CoronaVac

RCT
Phase 4
Adults aged ≥60 years without severe or unstable comorbidities or confirmed history of COVID-19 or SARS-CoV-2 infection at a single center in China. N=199
Low
Details

Full description

NCT05289037
Moderna + National Institute of Allergy and Infections Diseases (NIAID); ModernaTX
Branche A, medRxiv, 2022
New

Full text
Commentary
Commentary
Commentary
RNA based vaccine

2ndboost mRNA-1273Omicron + mRNA-1273Beta

2ndboost mRNA-1273Omicron + mRNA-1273 Delta

2ndboost mRNA-1273Omicron + mRNA-1273

2ndboost mRNA-1273 Omicron

2ndboost mRNA-1273

RCT
Phase 2
Adults with completed primary and booster COVID-19 vaccine series, either homologous or heterologous, and in stable health at 22 centers in USA. N=602
Some concerns
Details

Full description

NCT04952727
CanSino Biological Inc./Beijing Institute of Biotechnology ; Sinovac Research and Development Co., Ltd
Jin P, medRxiv, 2022 b
New

Full text
Commentary
Commentary
Heterologous vaccination scheme

CoronaVac/Ad5-nCoV

CoronaVac

RCT
Phase 4
Adults aged ≥60 years without severe or unstable comorbidities or confirmed history of COVID-19 or SARS-CoV-2 infection at a single center in China. N=100
Low
Details

Full description

TCTR20211027002
Pfizer/BioNTech+Fosun Pharma
Nantanee R, Vaccine, 2022

Full text
Commentary
Commentary
RNA based vaccine

ChadOx1/boostBNT(half)

ChadOx1/boostBNT

RCT
Phase 2
Healthy adult volunteers that were SARS-CoV-2 infection-free and had received 2 doses of ChAdOx as prime series, in a single centre in Thailand. N=100
Some concerns
Details

Full description

NCT05087368
Clover Biopharmaceuticals Inc./Dynavax ; AstraZeneca + University of Oxford
Costa Clemens, Open Forum Infect. Dis., 2022

Full text
Commentary
Commentary
Commentary
Commentary
Protein subunit

ChAdOx1-S/booster 9 mcg SCB-2019 + alum

ChAdOx1-S/booster 9 mcg SCB-2019 + CpG + alum

ChAdOx1-S/booster 30 mcg SCB-2019 + CpG + alum

ChadOx1/boostChadOx1

RCT
Phase 2
Adults including healthy or stable co-morbidities with no history of SARS-CoV-2 infection who had previously received 2 doses of ChAdOx1-S1-S vaccine 6 months (±4 weeks) before enrollment in 3 centers in Brazil N=120
Some concerns
Details

Full description